Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START UP: upadacitinib versus dupilumab in children with moderate to severe atopic dermatitis
2023-504713-76-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in atopic dermatitis (AD) comparing Upadacitinib with Dupilumab (2 arms). Primary endpoints: Percentage of participants achieving EASI 75 at Week 16 and vIGA-AD 0 or 1 with at least 2-point reduction at Week 16. Planned start Dec 2024; status: authorised.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-504713-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504713-76-00.